A Multicenter, Open-label, Single-arm Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Fostemsavir in Combination with Optimized Background Therapy (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their Current Combination Antiretroviral Therapy (cART) and Have Dual- or Triple-class Antiretroviral (ARV) Resistance
Latest Information Update: 25 Sep 2024
Price :
$35 *
At a glance
- Drugs Fostemsavir (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Acronyms SHIELD study
- 03 Apr 2024 Planned End Date changed from 1 Jun 2027 to 1 Jun 2028.
- 03 Apr 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2025.
- 13 Aug 2021 Status changed from not yet recruiting to recruiting.